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Abstract
Cyclic adenosine monophosphate (cAMP) is a crucial intracellular second
messenger molecule that converts extracellular molecules to intracellular signal
transduction pathways generating cell- and stimulus-specific effects. Importantly,
specific phosphodiesterase (PDE) subtypes control the amplitude and duration of
cAMP-induced physiological processes and are therefore a prominent
pharmacological target currently used in a variety of fields. Here we tested the
extracts from traditional Chinese medicine, Forsythia suspense seeds, which have
been used for more than 2000 years to relieve respiratory symptoms. Using
structural-functional analysis we found its major lignin, Forsynthin, acted as an
immunosuppressant by inhibiting PDE4 in inflammatory and immune cell.
Moreover, several novel, selective small molecule derivatives of Forsythin were
tested in vitro and in murine models of viral and bacterial pneumonia, sepsis and
cytokine-driven systemic inflammation. Thus, pharmacological targeting of PDE4
may be a promising strategy for immune-related disorders characterized by
amplified host inflammatory response.
Introduction
Phosphodiesterase (PDE) is an enzyme that catalyzes the hydrolysis of a
phosphodiester bond, most notably those of the second messenger cascade
molecules cyclic adenosine monophosphate (cAMP) and cyclic guanosine
monophosphate (cGMP). cAMP and cGMP bind to the regulatory units of
protein kinase A(PKA) allowing for phosphorylation thus transducing signal
cascades in the cell [1–3]. Consequently, by severing these cA/GMP-dependent
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pathways, PDE has an enormous clinical significance monitoring cAMP and
cGMP levels in cells. The PDE superfamily comprises 11 subfamilies, PDE1-11,
respectively, each utilizing different substrate specificities. For example, PDE4, 7,
and 8 strictly hydrolyze cAMP; PDE5, 6, and 9, on the other hand, only hydrolyze
cGMP while the other family members (PDE1, 2, 3, 10, 11) can target both cAMP
and cGMP for hydrolysation [4]. For many years, PDE enzymes have remained an
interest within the pharmaceutical industry, as inhibition of PDE can increase the
levels of cAMP or cGMP thus enhancing or prolonging their natural physiological
effects [5].
Currently, various small molecular compounds have been discovered to inhibit
PDEs. For example, caffeine, aminophylline, and IBMX are nonselective PDE
inhibitors [6] that increase intracellular cAMP, thereby activating PKA, thus
inhibiting tumor necrosis factor (TNF) and other inflammatory cytokines, and
reducing inflammation [7]. There are also selective PDE inhibitors. Specifically,
PDE3 inhibitors such as inamrinone and milrinone, are used for short-term
treatment of congestive heart failure [8], and Cilostazol used in the treatment of
intermittent claudication [9]. The PDE5 inhibitors Sildenafil, tadalafil and
vardenafil boost cGMP levels in penile tissue [10–12] and are used primarily for
erectile dysfunction, as well as having secondary indication in treatment of
pulmonary hypertension [13, 14]. Recently, an opium alkaloid, Papaverine, was
shown to inhibit PDE10 [15]. Among all of the PDE isoforms, PDE4 is the major
cAMP-degrading enzyme found in inflammatory and immune cells. Selectively
inhibiting PDE4 prevents the release of cytokines and other inflammatory factors
and hinders the production of reactive oxygen species [16, 17].
As the leading causes of infectious deaths in the US, sepsis and pneumonia are
pathognomonically linked to a burst in cytokine release, i.e. cytokine storm, from
pro-inflammatory cells including macrophages, lymphocytes, and polymorpho-
nuclear leukocytes [18] [19]. Cytokine storm occurs in response to infection with
virulent pathogens, host cell injury, or irritants that activate a multitude of
receptors on immune effector cells. Under some conditions it is exaggerated
(hypercytokinemia) and results in a fatal immune reaction with constant
activation of immune effector cells that produce sustained or supraphysiologic
levels of tumor necrosis factor (TNF), interleukin 1 (IL1), and interleukin-6 (IL6)
that results in severe tissue injury and often death. Thus, selectively inhibiting
PDE4 may ameliorate cytokine storm and prevent tissue injury.
The earliest Pharmacopoeia in the world, the ‘‘Tang Ben Cao’’, completed in
659 AD is the first known documentation of the Forsythia suspensa plant being
used to treat fever, flu-like, and inflammatory symptoms. Since then, it has been
habitually and widely used in Asia as one of the major traditional medicines.
Nowadays, the extract of Forsythia suspensa seeds is used to treat numerous
inflammatory diseases including but not limited to erysipelas, inflammation,
pharyngitis, pyrexia, tonsillitis, and ulcers [20, 21]. Moreover, it has been shown
in studies that the crude extract displays potential antibacterial, antiviral,
choleretic and antipyretic effects [22]. Medicinal chemistry studies on Forsythia
seeds have revealed phenolic compounds including lignans and flavonols which
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PLOS ONE | DOI:10.1371/journal.pone.0115937 December 30, 2014 2 / 14
are suspected to be responsible for the various biological activities of the herb
[22, 23]. In this study, we sought to better understand Forsythia lignan Forsythin
structure-function relationships and it was used to design and test a new class of
selective PDE4 inhibitors. These selective PDE4 inhibitors exert potent anti-
inflammatory activity in several murine models of inflammation.
Results
Forsythin is an in silico inhibitor of PDE4
Forsythin is one of the major bioactive compounds extracted from Forsythia
suspensa seeds (Fig. 1A–B) (27). An o-linked b-D-glucopyranosylated lignan,
Forsythin readily can be hydrolyzed to remove a glucose moiety (Fig. 1C). Using
the structure of the predicted metabolite, we assessed the virtual docking with
PDE4D (based on PyMol PDB 1 mkd.phg) using LibDock (Discovery Studio,
Accelrys Software Inc./BIOVIA, San Diego, CA) (Fig. 1D,E). Using ZINCPharmer
[24], we then generated a pharmacophore model (Fig. 1E top left) that enabled
the identification of over 100 high value targets from a 18.3 million purchasable
compound library. We refined this search by performing a computer based
docking analysis of the target compounds using LibDock (Discovery Studio 3.5)
and selected 14 compounds (Fig. 2) for further testing using an in vitro
phosphodiesterease activity assay.
Tested compounds exhibit high potency and selectivity towards
PDE4
Compounds 1–14 (Fig. 2) were tested in vitro using PDE-glo phosphodiesterase
assay (Promega, Madison, WI). Briefly, all the compounds were diluted in DMSO,
and the final concentrations in each assay were 100, 10, 1, 0.1, 0.01, 0.001,
0.0001 mM. For the PDE4 activity assay, 10 mU of purified PDE4D (Millipore)
was used per reaction. Compound 7, which is Forsythin, exhibited [IC50]
PDE458 mM. Other custom designed compounds such as 6, 9 and 13 exhibited
much greater potency with an [IC50] towards PDE4 ranging from 10–90 nM.
Impressively, all of the test compounds exhibited selectively toward PDE4, in as
much as the [IC50].80 mM with PDE3, 5, 7, and 10 (Fig. 3).
Tested compounds reduce TNF secretion in LPS stimulated
mouse RAW264.7 and human PBMCs
Compound 6, 7, 9 and 13 were also tested in LPS stimulated RAW264.7 (Fig. 4A)
and PBMC (Fig. 4B) cells to evaluate their ability to suppress TNF secretion.
Compound 7, which is Forsythin, exhibited [IC50] TNF58–10 mM in RAW264.7
and PBMC cells, which is comparable to its [IC50] PDE4. Other custom designed
compounds such as 6, 9 and 13 exhibited much greater potency with an [IC50]
towards TNF ranging from 25–400 nM. Specifically, compound 13 exhibited
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greatest potency towards PDE4 with [IC50]510 nM (Fig. 3), it also exhibited
comparable potency towards [IC50] TNF ranging from 25–75 nM (Fig. 4C).
PDE4 inhibitors ameliorate LPS-induced lung injury
To assess any in vivo anti-inflammatory activity, four compounds [C2, C6, C7 and
C9, 1 mg/kg, intraperitoneal (i.p.) injection] were administered in a LPS-induced
pneumonia model. Briefly, compounds were administered to mice at various
doses through an i.p. injection 10 min after mice were given LPS (i.t. 3 mg/kg).
Mice were then euthanized 16 h later using pentobarbital; BAL was collected and
assayed for IL1, IL6 and TNF cytokine levels. These compounds varied in their
ability to ameliorate lavage cytokines, protein concentration, and total cell counts
from LPS-treated mice (Fig. 5A–E). In addition, these inhibitors diminished
histological evidence of lung injury (Fig. 5F).
PDE4 inhibitors lessen cytokine storm induced by LPS septic
shock
As a widely used model of sepsis [25], selective PDE4 inhibitors (C6, 7 and 9) were
administered to mice at various doses through an i.p. injection, and 10 min later
mice were given LPS (E. coli, 100 ug i.p.). Mice were euthanized 2 h later using
pentobarbital where blood was collected and assayed for IL6 and TNF cytokine
levels. All inhibitors exhibited high potency in vivo (inhibitory dose [ID50]
TNF50.01,1 mg/kg, ID50 IL-650.1,1 mg/kg,) (Fig. 6A–B). In a separate
Fig. 1. Forsythin is an inhibitor of PDE4. A–C. The chemical structure of Forsythin extracted from Forsythia suspensa seeds. Forsythin is an o-linked b-D-
glucopyranosylated lignin that can be hydrolyzed (Red line). D. Predicted docking site of Forsythin with PDE4. E. Predicted residue electrostatic and van der
Waals interactions between PDE4 amino acids and Forsythin. Using ZINCPharmer [24], a pharmacophore model was generated (upper left) and used to
screen the lead compounds from an 18.3 million purchasable compound library.
doi:10.1371/journal.pone.0115937.g001
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experiment, a brief pharmacokinetic study was performed where PDE4 inhibitors
(1 mg/kg, i.p.) were given to mice 18 h before LPS administration (E. coli, 100 ug
i.p.). Compound 9 demonstrated excellent efficacy reducing both serum TNF and
IL-6 cytokines even after 18 h lead time (Fig. 6C–D).
PDE4 inhibitors reduce H1N1 influenza-induced lung injury
To further test these compounds, mice were challenged with H1N1 (105 pfu/mose
i.t.) without (vehicle control) or with C6, C7, C9, or C13 treatment (30 mg/ml
added to drinking water containing 2% sucrose: estimated dose55 mg/kg/d). All
four PDE4 inhibitors significantly improved the survival of mice infected with
H1N1 compared with mice receiving diluent (Fig. 7A). The PDE inhibitors also
decreased lavage cell counts, protein concentrations, and lavage cytokine IL-6 and
TNF (Fig. 7B–E). Impressively, PDE4 inhibitors also significantly reduced serum
cytokines induced from the H1N1-induced systematic inflammation (Fig. 7F,G).
The tested compounds were also able to lessen signs of tissue injury (Fig. 7H).
These results suggest that the selective PDE4 inhibitors suppress inflammation
and preserve lung homeostasis after pulmonary H1N1 infection.
Fig. 2. Molecular structures of selected compounds. Over 100 high value lead compounds were generated through ZINCPharmer. These compounds
were then refined by a computer based docking analysis using LIBDOCK (Discovery Studio 3.5). Among the top scoring compounds, 14 compounds were
selected for further testing using an in vitro phosphodiesterase activity assay.
doi:10.1371/journal.pone.0115937.g002
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Fig. 3. Tested compounds exhibit high potency and selectivity towards PDE4. For the PDE activity assay, all test compounds were diluted in DMSO
with final concentrations in each assay of 100, 10, 1, 0.1, 0.01, 0.001, 0.0001 mM. For the PDE4 activity assay, 10 mU of purified PDE4 (Millipore) was used
per reaction. Compounds 6, 7, 9 and 13 (blue underline) were further tested in PDE3, 5, 7, 10 activity assays in which 25 mU of purified enzyme was used
per reaction. Summary of compound IC50 in lower right corner.
doi:10.1371/journal.pone.0115937.g003
Fig. 4. Tested compounds reduce TNF secretion in LPS stimulated mouse RAW264.7 and human PBMCs. A. 56105 RAW264.7 cells were seeded in
96 wells for 18 h. Cells were primed with compounds at different concentration for 3 h before treated with LPS (1 ng/ml) for additional 8 h. TNF cytokine
releases were monitored by ELISA. B. PBMC (0.2 ml at 16105/ml) were primed with compounds at different concentration for 3 h before treated with LPS
(1 ng/ml) for additional 8 h. TNF cytokine releases were monitored by ELISA. % of TNF secretion were calculated and graphed. C. Summary of compound
IC50. The data represent n53–6 experiments.
doi:10.1371/journal.pone.0115937.g004
PDE4 Inhibitors in Forsythia
PLOS ONE | DOI:10.1371/journal.pone.0115937 December 30, 2014 6 / 14
Discussion
It has been known for years that increased cAMP from PDE4 inhibition or gene
knockout were able to markedly decrease inflammatory responses in immune cells
[26]. cAMP controls inflammation through several distinct pathways, including
cyclic nucleotide-gated ion channels, cAMP-activated protein kinases (PKA), or
exchange proteins directly activated by cAMP (Epac) [27]. Specifically, cAMP
actives PKA, negatively regulates NF-KB pathway, thus suppressing the release of
proinflammatory mediators (eg, TNF-a, interleukin-17, Interferon-c) [28].
Moreover, cAMP actives transcriptions of anti-inflammatory gene such as
interleukin-10 through transcription factor CREB (cAMP response element-
binding protein) [29]. Thus, pharmacological targeting of PDE4 may be a
promising strategy for anti-inflammatory therapy.
Here we developed a novel class of selective PDE4 inhibitors that exert robust
anti-inflammatory activity by impairing cytokine release in three preclinical
models. The structural basis for our drug design emerged from Forsythin, the one
of major compound extracted from Forsythia suspensa seeds. Among the 14
compounds tested in this study, synthetic compounds 6, 9 and 13 showed the
potent IC50 (10–90 nM) toward PDE4. Impressively, these compounds also
exhibit high selectivity toward PDE4, with .80 mM IC50 towards other PDE
Fig. 5. PDE4 inhibitors ameliorate LPS induced lung injury. C57/BL6 mice were challenged with LPS (E.coli, 3 mg/kg, i.t.) followed by i.p. administration
of vehicle, 1 mg/kg of compound 2, 6, 7 or 9. Mice were then euthanized 18 h later using pentobarbital, and lungs were lavaged with saline, harvested, and
then homogenized. Lavage cytokine secretion (A–C), protein concentrations (D) and cell counts (E) were measured. F. H&E staining was performed on lung
samples. Original magnification, 620. The data represent n54–6 mice/group, *P,0.05 versus vehicle.
doi:10.1371/journal.pone.0115937.g005
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enzymes (Fig. 3). Compounds 6, 9 and 13 also showed potent IC50 (20–450 nM)
toward TNF inhibition in LPS stimulated RAW274.7 and PBMC cells. Many
natural compounds, such as the flavonoid derivatives Hesperetin and prunetin,
were also isolated from traditional Chinese medicines are selective inhibitors of
PDE4 with an IC50 ranging from 10–100 mM [30]. However, little is known about
the structure–activity relationship between such lignans or their inhibitory effect
on proteins in the inflammatory pathway. In this study, we determined that o-
linked b-D-glucopyranosided lignan Forsythin is a weak but selective inhibitor of
PDE4. Structurally speaking, compound 6 and Forsythin are highly similar except
that Forsythin is an o-linked b-D-glucopyranoside. In vitro, Forsythin is .80
times weaker in activity toward PDE4 compared with compound 6. However, our
in vivo study suggested that Forsythin and compound 6 exhibit similar activities
in several murine models (Fig. 5A, 6C, 7B). This suggests that Forsythin may act
as a prodrug that its glucopyranoside group will be potentially removed in vivo by
b-glucosidase, and release the active lignin; which is a common of metabolic
reaction in plant lignans and flavonols [31, 32].
Pandemic H5N1 Influenza virus and SARS virus are known to cause dangerous
cytokine storm resulting in severe damage to alveoli and lung tissue and thus
Fig. 6. PDE4 inhibitors lessen cytokine storm induced by LPS septic shock. C57/BL6 mice were administered i.p. nothing (CON), vehicle, 10 ug/kg,
100 ug/kg, 1 mg/kg or 10 mg/kg of compounds 6, 7 or 9. Mice were given LPS (E. coli, 100 mg) 10 min later through an i.p. injection. 2 h later mice were
euthanized using pentobarbital and blood was collected for IL-6 and TNF measurements. Shown in panel A–B is the % inhibition of cytokine levels as a
function of drug dose. The data represent n53 mice/group at each dose. C57/BL6 mice were also pretreated with compound 5, 6, 7 or 9 at 1 mg/kg. Mice
were given LPS (E. coli, 100 mg) 18 h later through an i.p. injection. 2 h later the mice were euthanized using pentobarbital and blood was collected for IL-6
and TNF measurements (C–D). The data represent n54–6 mice/group, *P,0.05 versus vehicle.
doi:10.1371/journal.pone.0115937.g006
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extremely high mortality rates [33, 34]. Today, viral pneumonia affects more than
100 million children and 100 million adults per year yet there are no effective
treatments only supportive care [35]. Our H1N1 murine model recapitulates well
with the deadly human viral pneumonia, as H5N1 Influenza infection is largely
driven by an exuberant host response and amplification of cytokines and
chemokines that contribute to influenza-induced morbidity and mortality
[25, 36, 37]. Our pulmonary viral infection model was complemented with a
murine sepsis model to provide assessment of PDE4 inhibitors on systemic
inflammation by the endotoxin LPS [37, 38]. Importantly, in each of these models
of inflammation, our PDE4 inhibitors (Compound 6, 7, 9, 13) were observed to
lessen severity of tissue injury using varying modes of application (parenteral,
oral), and none of the animals treated with the agents exhibited overt signs of
distress. The dosing of these compounds also appeared to be excellent in vivo,
with ,1 mg/kg efficacious dose in both LPS pneumonia and sepsis model.
Specifically, these compounds also appeared to have long half-life in vivo. As
shown in Fig. 6C–D, the septic shock model was carried out 18 h after the initial
treatment (1 mg/kg, i.p.), yet we still observed a 40–60% decrease in serum
cytokines.
Fig. 7. PDE4 inhibitors reduce H1N1 influenza-induced lung injury. C57/BL6 mice were challenged with H1N1 (105 pfu/mouse, i.t.) for up to 6 days. For
compound treatment, a stock solution (5 mg/ml) was added to the drinking water (containing 2% sucrose) to a final concentration of 30 mg/ml. A. Survival
studies of mice administered i.t. with H1N1 (105 pfu/mouse, n56 mice/group). Mice were then euthanized using pentobarbital and lungs were lavaged with
saline, harvested, and then homogenized. Cell counts and lavage protein were measured (B, C). Lavage cytokine secretions were measured (D, E). Serum
samples were also collected and cytokine levels were measured (F, G). H. H&E staining was performed on lung samples. Original magnification,660. The
data represent n54–6 mice/group, *P,0.05 versus vehicle.
doi:10.1371/journal.pone.0115937.g007
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PLOS ONE | DOI:10.1371/journal.pone.0115937 December 30, 2014 9 / 14
Overall, our pre-clinical studies demonstrate the biological efficacy of selective
PDE4 inhibitors in murine models where both infectious and irritant factors
trigger cytokine release. These selective PDE4 inhibitors could potentially have
broad applications in acute and chronic inflammatory diseases. In fact the
selective PDE4 inhibitor, Roflumilast, recently became the first FDA approved
PDE4 inhibitor on the market [39, 40]. Roflumilast is a potent anti-inflammatory
drug, particularly in pulmonary diseases such as asthma, COPD, and rhinitis.
Thus, PDE4 is a potentially important drug target for the treatment of
inflammatory diseases. However, further research and development clearly is
needed to carefully ascertain the safety profile, distribution, elimination, and
metabolism of these new chemical entities in larger models of inflammation.
Successful results from these pharmacokinetic studies will set the stage for




RAW 264.7 cells were from ATCC. PBMCs were from Sanguine Life Sciences.
PDE4 activity assay kit was from Promega. IL1b, TNFa, IL6 mouse ELISA kit,
human TNFa were from R&D systems. LPS (E.coli) were from Sigma. Forsythin
was from Stanford Chemicals; all other synthetic compounds were purchased
from ChemDiv, Inc. and Vitas-M Laboratory, Ltd. All compounds are.98% pure
by HPLC.
Animal studies
All animal experiments were approved by the University of Pittsburgh
Institutional Animal Care and Use Committee (IACUC) under protocol
(14023127). Mice were housed at University of Pittsburgh Animal Care Facility
and maintained according to all federal and institutional animal care guidelines.
Method of sacrifice
All mice were euthanized using i.p. injection of 100 mg/kg pentobarbital
approved by University of Pittsburgh Institutional Animal Care and Use
Committee (IACUC) under protocol (14023127).
Sepsis model
Male C57LB/6 mice (purchased from Jackson Laboratories) were acclimated at the
University of Pittsburgh Animal Care Facility and maintained according to all
federal and institutional animal care guidelines and under a University of
Pittsburgh Institutional Animal Care and Use Committee (IACUC)-approved
protocol (14023127). Male C57LB/6 Mice were deeply anesthetized with ketamine
(80 to 100 mg/kg of body weight, intraperitoneally [i.p.]) and xylazine (10 mg/kg,
PDE4 Inhibitors in Forsythia
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i.p.). Compounds were diluted in PBS and various amounts (0.01, 0.1, 1 and
10 mg/kg) of compounds were administered to mice though an i.p. injection.
10 min later, mice were given 100 mg of LPS (E. coli) through an i.p. injection. 2 h
later, mice were euthanized. Plasma was collected and processed for cytokine
assays.
LPS Pneumonia modes
Male C57LB/6 mice (purchased from Jackson Laboratories) were acclimated at the
University of Pittsburgh Animal Care Facility and maintained according to all
federal and institutional animal care guidelines and under a University of
Pittsburgh Institutional Animal Care and Use Committee (IACUC)-approved
protocol (14023127). Male C57LB/6 Mice were deeply anesthetized with ketamine
(80 to 100 mg/kg of body weight, intraperitoneally [i.p.]) and xylazine (10 mg/kg,
i.p.), and then the larynx was well visualized under a fiber optic light source before
endotracheal intubation with a 3/400 24-gauge plastic catheter. Compounds were
diluted in PBS and administered to mice at 1 mg/kg through an i.p. injection
10 min after mice were given with LPS (i.t. 3 mg/kg). Mice were then euthanized
18 h later; Lavage fluids were collected from mice to measure protein and
cytokine concentration. Lungs were isolated from mice for H&E staining.
H1N1 Pneumonia model
Male C57LB/6 mice (purchased from Jackson Laboratories) were acclimated at the
University of Pittsburgh Animal Care Facility and maintained according to all
federal and institutional animal care guidelines and under a University of
Pittsburgh Institutional Animal Care and Use Committee (IACUC)-approved
protocol (14023127). Male C57LB/6 Mice were deeply anesthetized with ketamine
(80 to 100 mg/kg of body weight, intraperitoneally [i.p.]) and xylazine (10 mg/kg,
i.p.), and then the larynx was well visualized under a fiber optic light source before
endotracheal intubation with a 3/400 24-gauge plastic catheter. 50 ul of H1N1 (A/
PR/8/34, 105 pfu/mouse) was instilled i.t. and mice monitored for up to 6 d. For
compound treatment, a stock solution (5 mg/ml) was added to the drinking water
(containing 2% sucrose) to a final concentration of 30 mg/ml. For survival studies,
mice were carefully monitored and weighted over time; mice that lost .20%
weight and moribund, preterminal mice were immediately euthanized and
recorded as deceased. Lavage fluids were collected from mice to measure protein
and cytokine concentration. Lungs were isolated from mice for H&E staining.
In silico docking study
Docking study was carried using Libdock program within Discovery Studio 3.5.
PDE4D crystal structural 1MKD.pdb was used in this docking study. Protein
cavity and potential drug binding site were first determined (X: 44.976, Y: 7.389,
Z: 124.713, radius 10.8). Libdock program parameters were: Number of Hotspots:
100, Docking tolerance: 0.25, Docking Preference: High quality, Conformation
PDE4 Inhibitors in Forsythia
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method: Fast, Minimization Algorithm: Do not minimize, Parallel Processing:
True. After the docking study, the top score-ranking molecules were selected and
evaluated further.
PDE activity assay
A PDE activity assay was carried out using the PDE-Glo Phosphodiesterase Assay
per manufacturer’s instruction (Promega). Briefly, 5 ul of 1X PDE-Glo Reaction
buffer containing 10 mU of purified human recombinant PDE4A4 (Millipore)
was added to 96 well plate. All test compounds were dissolved in DMSO and a
serial dilution (110) of the inhibitors were performed using 1X PDE-Glo Reaction
buffer. 7.5 ul of test compounds were added to the PDE enzyme with the final
concentrations in each assay of 100, 10, 1, 0.1, 0.01, 0.001, 0.0001 mM, and
incubated at room temperature for 10 min. To initiate the PDE reaction, 12.5 ul
of 2 mM cAMP was added to to each reaction, mixed well and incubate at room
temperature for 10 min. The reactions were terminated using 12.5 ul of PDE-Glo
Termination Buffer. 12.5 ul of PDE-Glo Detection Solution containing PDE-Glo
Detection Buffer and Protein Kinase A was added to each reaction. The reactions
were carried at room temperature for 20 min. 50 ul of Kinase-Glo Reagent was
then added to each reaction, mixed well, and incubate for 10 minutes at room
temperature. The chemical luminescence signals were measured, quantified and
graphed. Compounds 6, 7, 9 and 13 were further tested similarly using 25 mU
purified PDE3, 5, 7, 10 (Millipore) enzyme.
LPS induced cytokine release in RAW264.7 and PBMC cells
56105 RAW264.7 cells were seeded in 96 wells for 18 h. Cells were primed with
compounds at different concentration for 3 h before treated with LPS (1 ng/ml)
for additional 8 h. TNF cytokine releases were monitored by ELISA. PBMC
(0.2 ml at 16105/ml) were primed with compounds at different concentration for
3 h before treated with LPS (1 ng/ml) for additional 8 h. TNF cytokine releases
were monitored by ELISA. % of TNF secretion were calculated and graphed.
Statistical Analysis
Statistical comparisons were performed with the Prism program, version 4.03
(GraphPad Software, Inc., San Diego, CA) using an ANOVA 1 or an unpaired 2 t-
test with p,0.05 indicative of significance.
Author Contributions
Conceived and designed the experiments: BBC. Performed the experiments: TAC
ACM NMW TL BBC. Analyzed the data: RLB GDL BBC. Contributed to the
writing of the manuscript: TAC ACM TL GDL BBC.
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